Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
Abstract Recent advancements in the field of immune-oncology have led to a significant increase in life expectancy of patients with diverse forms of cancer, such as hematologic malignancies, melanoma and lung cancer. Unfortunately, these encouraging results are not observed in the majority of patien...
Main Authors: | Q. Lecocq, P. Debie, J. Puttemans, R. M. Awad, L. De Beck, T. Ertveldt, Y. De Vlaeminck, C. Goyvaerts, G. Raes, M. Keyaerts, K. Breckpot, N. Devoogdt |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-11-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13550-021-00857-9 |
Similar Items
-
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
by: Quentin Lecocq, et al.
Published: (2019-09-01) -
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
by: Katty Zeven, et al.
Published: (2023-09-01) -
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
by: Katrijn Broos, et al.
Published: (2019-06-01) -
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development
by: Yannick De Vlaeminck, et al.
Published: (2020-11-01) -
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
by: Quentin Lecocq, et al.
Published: (2020-12-01)